Medications Associated with Increased Risk of Keratinocyte Carcinoma

Dermatol Clin. 2019 Jul;37(3):297-305. doi: 10.1016/j.det.2019.02.005. Epub 2019 Apr 16.

Abstract

A number of medications for short-term and long-term use have been linked to an increased risk for keratinocyte carcinoma (KC). Immunosuppressive medications are associated with an increased risk for KC and melanoma due to reduction of antitumor immune surveillance, and some immunosuppressive agents directly impact DNA replication and repair. Clinical and epidemiologic studies have shown an increased risk for KC in users of photosensitizing medications. Additional mechanisms include drug-induced modulation of DNA damage repair, enhancement of keratinocyte proliferation, and direct carcinogenic effect. Alternatively, some medications potentially decrease KC risk. This article reviews the literature on medications associated with KC risk.

Keywords: Carcinogen; Immunosuppression; Keratinocyte carcinoma; Medication; Photosensitization.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Calcineurin Inhibitors / therapeutic use
  • Carcinoma, Basal Cell / epidemiology*
  • Carcinoma, Squamous Cell / epidemiology*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Keratinocytes / pathology
  • Molecular Targeted Therapy
  • Risk Factors
  • Skin Neoplasms / epidemiology*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Infective Agents
  • Antihypertensive Agents
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • MTOR protein, human
  • TOR Serine-Threonine Kinases